GlassScriptPhysician profile
Salvatore Anthony Ciliberti
NPI 1770506073
$3,193.62
in general payments reported to CMS, 2019-2025
28 companies · $256 in 2025
The $256 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $146 · 2020: $333 · 2021: $639 · 2022: $649 · 2023: $507 · 2024: $663 · 2025: $256.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,407 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,407.17 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $542.84 | 2021-2024 | Vraylar, Ubrelvy, Qulipta |
| Amgen INC. | $395.91 | 2019-2024 | Otezla, Repatha |
| Pfizer INC. | $290.62 | 2019-2025 | |
| Esperion Therapeutics, INC. | $279.63 | 2020-2024 | Nexletol |
| Lilly USA, LLC | $273.70 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $205.71 | 2019-2024 | Farxiga, Fasenra |
| Novo Nordisk INC | $200.91 | 2020-2025 | Ozempic, Rybelsus |
| Welch Allyn | $185.58 | 2021 | |
| Merck Sharp & Dohme LLC | $106.94 | 2022-2025 | Capvaxive, Gardasil 9, Gardasil |
| Exact Sciences Corporation | $82.77 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $76.87 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $61.66 | 2024-2025 | Trintellix |
| Astellas Pharma US INC | $49.51 | 2021-2024 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $48.47 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.08 | 2022-2024 | Ofev |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $44.67 | 2021-2023 | |
| Inspire Medical Systems, INC. | $43.76 | 2024-2025 | Inspire |
| Axsome Therapeutics, INC. | $42.42 | 2024 | Auvelity |
| Seqirus USA INC | $38.08 | 2019-2025 | Flucelvax, Fluad |
| Idorsia Pharmaceuticals US INC | $35.24 | 2023 | Quviviq |
| Sanofi Pasteur INC. | $25.60 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $23.73 | 2022 | |
| Janssen Pharmaceuticals, INC | $20.02 | 2022 | |
| Sanofi-Aventis U.S. LLC | $15.69 | 2019 | |
| Currax Pharmaceuticals LLC | $15.65 | 2023 | Contrave |
| Eisai INC. | $14.30 | 2020 | |
| Alexion Pharmaceuticals, INC. | $13.95 | 2022 | |
| Allergan, INC. | $11.31 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Salvatore Ciliberti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.